Kinase inhibitors as potential agents in the treatment of multiple myeloma

Recent years have witnessed a dramatic increase in the number of therapeutic options available for the treatment of multiple myeloma (MM) - from immunomodulating agents to proteasome inhibitors to histone deacetylase (HDAC) inhibitors and, most recently, monoclonal antibodies. Used in conjunction wi...

Descripción completa

Detalles Bibliográficos
Autor principal: Abramson, Hanley N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348443/
https://www.ncbi.nlm.nih.gov/pubmed/27655636
http://dx.doi.org/10.18632/oncotarget.10745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348443/
https://www.ncbi.nlm.nih.gov/pubmed/27655636
http://dx.doi.org/10.18632/oncotarget.10745

Ejemplares similares